FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma
2024-02-14
临床3期临床结果上市批准快速通道
Preview
来源: Pharmaceutical Technology
Ipsen’s Onivyde regimen is indicated as a first-line treatment for metastatic pancreatic adenocarcinoma. Credit: MattL_Images / Shutterstock.com.
The US Food and Drug Administration approved Ipsen‘s supplemental new drug application for the Onivyde (irinotecan liposome injection) combination regimen (NALIRIFOX) as a first-line treatment for metastatic pancreatic adenocarcinoma (mPDAC) in adults.
The treatment is indicated for use with oxaliplatin, fluorouracil and leucovorin.
It is the second FDA approval for an Onivyde regimen in mPDAC, expanding treatment options for patients.
In 2015, the regulator approved Onivyde plus fluorouracil and leucovorin in patients experiencing disease progression following gemcitabine-based therapy.
The latest approval is based on findings from the Phase III NAPOLI 3 clinical trial.
See Also:FDA grants fast track status to Edgewise’s Duchenne treatment
Preview
来源: Pharmaceutical Technology
SCOPE: FDA facilitates AI and ML use for clinical trials and drug development
Preview
来源: Pharmaceutical Technology
The open-label, randomised trial enrolled 770 individuals across 187 sites in 18 countries.
The trial met its primary and secondary endpoints, showing improvements in survival rates for subjects treated with the Onivyde regimen compared to those receiving nab-paclitaxel and gemcitabine.
Patients treated with the Onivyde regimen, NALIRIFOX, experienced a median overall survival of 11.1 months, notably longer than the 9.2 months observed in patients treated with nab-paclitaxel and gemcitabine.
The Onivyde combination also led to a median progression-free survival of 7.4 months, compared to 5.6 months under the alternative treatment.
The objective response rate for the NALIRIFOX regimen was 41.8%, against the 36.2% rate for those receiving nab-paclitaxel and gemcitabine.
Despite the potential for serious adverse events such as fatal neutropenic fever and severe diarrhoea, the safety profile of the Onivyde regimen was deemed manageable.
Ipsen Research and Development EVP and head Christelle Huguet stated: “With today’s approval, this Onivyde (NALIRIFOX) regimen can now offer a potential new standard-of-care treatment option with proven survival benefits for people living with metastatic pancreatic adenocarcinoma in the US.”
In August 2023, Ipsen received FDA approval for Sohonos (palovarotene) capsules to treat fibrodysplasia ossificans progressiva.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。